Appleton Partners’s AC Immune ACIU Stock Holding History

Appleton Partners’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-11,525	Closed	-$57K	–	289
2019 Q3	$57K	Sell	11,525 -3,835	-25%	-$20.5K	0.01%	278
2019 Q2	$85K	Buy	+15,360	New	+$78.3K	0.01%	277

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Appleton Partners's ACIU Position: Q4 2019 in Review

Appleton Partners sold out of AC Immune (ACIU) in Q4 2019, closing a stake of 11,525 shares — an estimated $57K sold.

Appleton Partners first reported a position in ACIU in Q2 2019 and held it in 2 quarters. The position peaked at $85K in Q2 2019. 48 funds tracked by Wall St. Rank hold ACIU as of Q4 2019.

Appleton Partners reported no remaining AC Immune position as of Q4 2019 after selling out during the quarter.
Appleton Partners sold 11,525 AC Immune shares in Q4 2019, an estimated $57K.
Appleton Partners first reported a position in AC Immune in Q2 2019 and held it in 2 quarters.
Appleton Partners's AC Immune position peaked at $85K in Q2 2019.
48 funds tracked by Wall St. Rank held AC Immune as of Q4 2019.

Based on Appleton Partners's 13F filing for Q4 2019, filed 13 Jan 2020.